EP2336183A3 - Antikörper gegen CCR5 und deren Verwendung - Google Patents

Antikörper gegen CCR5 und deren Verwendung Download PDF

Info

Publication number
EP2336183A3
EP2336183A3 EP10191497A EP10191497A EP2336183A3 EP 2336183 A3 EP2336183 A3 EP 2336183A3 EP 10191497 A EP10191497 A EP 10191497A EP 10191497 A EP10191497 A EP 10191497A EP 2336183 A3 EP2336183 A3 EP 2336183A3
Authority
EP
European Patent Office
Prior art keywords
seq
nos
group
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10191497A
Other languages
English (en)
French (fr)
Other versions
EP2336183A2 (de
Inventor
Michael Brandt
Suryanarayana Sankuratri
Ralf Schumacher
Stefan Seeber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP10191497A priority Critical patent/EP2336183A3/de
Publication of EP2336183A2 publication Critical patent/EP2336183A2/de
Publication of EP2336183A3 publication Critical patent/EP2336183A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP10191497A 2005-04-01 2006-03-31 Antikörper gegen CCR5 und deren Verwendung Withdrawn EP2336183A3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10191497A EP2336183A3 (de) 2005-04-01 2006-03-31 Antikörper gegen CCR5 und deren Verwendung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05007138 2005-04-01
EP10191497A EP2336183A3 (de) 2005-04-01 2006-03-31 Antikörper gegen CCR5 und deren Verwendung
EP06723934A EP1869087A2 (de) 2005-04-01 2006-03-31 Antikörper gegen ccr5 und anwendungen davon

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP06723934.3 Division 2006-03-31
WOPCT/EP2006/002974 Previously-Filed-Application 2006-03-31

Publications (2)

Publication Number Publication Date
EP2336183A2 EP2336183A2 (de) 2011-06-22
EP2336183A3 true EP2336183A3 (de) 2011-10-12

Family

ID=34934663

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10191497A Withdrawn EP2336183A3 (de) 2005-04-01 2006-03-31 Antikörper gegen CCR5 und deren Verwendung
EP06723934A Withdrawn EP1869087A2 (de) 2005-04-01 2006-03-31 Antikörper gegen ccr5 und anwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06723934A Withdrawn EP1869087A2 (de) 2005-04-01 2006-03-31 Antikörper gegen ccr5 und anwendungen davon

Country Status (19)

Country Link
US (1) US7615216B2 (de)
EP (2) EP2336183A3 (de)
JP (2) JP4733736B2 (de)
KR (1) KR20070116136A (de)
CN (1) CN101175771A (de)
AR (1) AR052959A1 (de)
AU (1) AU2006228663A1 (de)
BR (1) BRPI0609792A2 (de)
CA (1) CA2603692A1 (de)
CR (1) CR9393A (de)
IL (1) IL186071A0 (de)
MA (1) MA29374B1 (de)
MX (1) MX2007011842A (de)
NO (1) NO20074867L (de)
RU (1) RU2007139953A (de)
SG (1) SG151284A1 (de)
TW (1) TW200720289A (de)
WO (1) WO2006103100A2 (de)
ZA (1) ZA200708332B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525301A (ja) * 2006-01-30 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｉｖを処置するための相乗的組成物
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR20100097737A (ko) * 2008-01-15 2010-09-03 에프. 호프만-라 로슈 아게 Ｃｃｒ５에 대한 어푸코실화된 항체 및 이의 용도
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
EP2475991A1 (de) 2009-09-07 2012-07-18 F. Hoffmann-La Roche AG Es-ms aus glykopeptiden zur glykosyierungsanalyse
EP2478013B1 (de) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled-coil- und/oder tether-haltige proteinkomplexe und verwendungen davon
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2678358B1 (de) * 2011-02-23 2015-07-22 F.Hoffmann-La Roche Ag Antikörper gegen humanes il33r und ihre verwendung
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6041882B2 (ja) 2011-09-23 2016-12-14 ロシュ グリクアート アーゲー 二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
AU2019302603A1 (en) 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
JP7638989B2 (ja) 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6743594B1 (en) * 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
EP0983303B1 (de) 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
US6610834B1 (en) 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2355607A1 (en) 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
ES2233359T3 (es) 1999-03-11 2005-06-16 Micromet Ag Construcciones de anticuerpos dirigidos contra el ccr5 y su empleo en el tratamiento de enfermedades autoinmunologicas.
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
EP1263791A4 (de) * 2000-02-09 2004-07-07 Human Genome Sciences Inc Menschlicher g-protein chemokinrezeptor hdgnr10 (ccr5 rezeptor)
US20040043033A1 (en) 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
EP1207202A1 (de) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nukleinsäuremoleküle, welche für ein Protein kodieren, das mit dem Chemokinrezeptor oder anderen Mitgliedern der Chemokinrezeptorfamilie interagiert
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
NZ534947A (en) 2002-02-22 2008-03-28 Progenics Pharm Inc Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell.
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AARONS EMMA J ET AL: "Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7", VIROLOGY, vol. 287, no. 2, 1 September 2001 (2001-09-01), pages 382 - 390, XP002329620, ISSN: 0042-6822 *
LEHNER T: "The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 23, no. 7, 1 July 2002 (2002-07-01), pages 347 - 351, XP004367754, ISSN: 1471-4906 *
SICILIANO SALVATORE J ET AL: "A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 4, 22 January 1999 (1999-01-22), pages 1905 - 1913, XP002329621, ISSN: 0021-9258 *
STEINBERGER P ET AL: "GENERATION AND CHARACTERIZATION OF A RECOMBINANT HUMAN CCR5-SPECIFIC ANTIBODY A PHAGE DISPLAY APPROACH FOR RABBIT ANTIBODY HUMANIZATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 46, 17 November 2000 (2000-11-17), pages 36073 - 36078, XP000999141, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
MA29374B1 (fr) 2008-04-01
NO20074867L (no) 2007-12-07
CR9393A (es) 2008-02-20
TW200720289A (en) 2007-06-01
SG151284A1 (en) 2009-04-30
WO2006103100A3 (en) 2006-12-28
WO2006103100A2 (en) 2006-10-05
US20070036796A1 (en) 2007-02-15
KR20070116136A (ko) 2007-12-06
BRPI0609792A2 (pt) 2010-04-27
AU2006228663A1 (en) 2006-10-05
MX2007011842A (es) 2007-10-11
US7615216B2 (en) 2009-11-10
JP4733736B2 (ja) 2011-07-27
AR052959A1 (es) 2007-04-11
JP2008533998A (ja) 2008-08-28
EP2336183A2 (de) 2011-06-22
RU2007139953A (ru) 2009-05-10
JP2011079836A (ja) 2011-04-21
CN101175771A (zh) 2008-05-07
IL186071A0 (en) 2008-01-20
ZA200708332B (en) 2009-04-29
CA2603692A1 (en) 2006-10-05
EP1869087A2 (de) 2007-12-26

Similar Documents

Publication Publication Date Title
EP2336183A3 (de) Antikörper gegen CCR5 und deren Verwendung
EP2471817A3 (de) Für Il-31 spezifische humanisierte Antikörpermoleküle
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP2426146A3 (de) Monoklonale anti-humane IL-21-Antikörper
EP3181585A3 (de) Antigene gm-csf-peptide und gm-csf-antikörper
NL300911I2 (nl) sarilumab
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP2759549A3 (de) IL-31-monoklonale Antikörper und Verfahren zu deren Verwendung
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ599497A (en) Humanized antibodies to amyloid beta
NZ596042A (en) Humanized anti-factor d antibodies
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EP4435009A3 (de) Claudin6-antikörper und verfahren zur behandlung von krebs
NZ605980A (en) Anti-fap antibodies and methods of use
NZ599683A (en) Anti-ilt7 antibody
GEP20074222B (en) Antibodies to cd40
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
NZ593068A (en) IL-18 antibody
EP2305716A3 (de) Antikörper gegen gpnmb und ihre verwendungen
NZ598670A (en) Antibodies against glucagon receptor and their use
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008063771A3 (en) Anti-cd20 antibodies and methods of use
NZ600899A (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1869087

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR YU

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR YU

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20110908BHEP

17P Request for examination filed

Effective date: 20120412

17Q First examination report despatched

Effective date: 20120605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121016